Analyst Ratings for Intra-Cellular Therapies (ITCI)

ITCI Rating Summary

  |   Expand Research on ITCI
Overall Rating: NEUTRAL   Rating Trend: =   Avg. $ Target: N/A
Rating Score: 4.5 / 10   Percentile Rank: 46%
Date Firm Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
2/28/2025 Canaccord Sumant Kulkarni Upgrade Buy
(Hold)		 132.00
(N/A)		 128.25
(131.87)		 2.82% Details
2/24/2025 Mizuho Graig Suvannavejh Downgrade Neutral
(Outperform)		 132.00
(140.00)		 1.00
(131.87)		 13087% Details